Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date (Descending) Status
68180-0738-01 68180-0738 decitabine decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Dec. 6, 2019 Jan. 1, 2040 In Use
60505-6050-04 60505-6050 Bortezomib BORTEZOMIB 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 2, 2022 Dec. 31, 2028 In Use
60505-6065-00 60505-6065 Pemetrexed disodium Pemetrexed 100.0 mg/4mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Dec. 31, 2028 In Use
60505-6066-00 60505-6066 Pemetrexed disodium Pemetrexed 500.0 mg/20mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Dec. 31, 2028 In Use
60505-6067-00 60505-6067 Pemetrexed disodium Pemetrexed 1000.0 mg/40mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Dec. 31, 2028 In Use
60505-6068-00 60505-6068 Pemetrexed disodium Pemetrexed 750.0 mg/30mL Chemotherapy Antimetabolite Folic Acid Analog Intravenous May 25, 2022 Dec. 31, 2028 In Use
67457-0847-44 67457-0847 Trastuzumab OGIVRI 420.0 mg/ 20 mL Immunotherapy Monoclonal Antibody HER2 Intravenous Nov. 29, 2019 April 30, 2027 In Use
67457-0991-15 67457-0991 Trastuzumab OGIVRI 150.0 mg/7.4mL Immunotherapy Monoclonal Antibody HER2 Intravenous Nov. 29, 2019 Feb. 28, 2027 In Use
67457-0833-06 67457-0833 Pegfilgrastim Fulphila 6.0 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor Subcutaneous July 9, 2018 May 31, 2026 In Use
69543-0371-10 69543-0371 Palonosetron hydrochloride Palonosetron hydrochloride 0.25 mg/5mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Sept. 19, 2018 Jan. 31, 2026 In Use
69660-0201-91 69660-0201 Rucaparib Rubraca 200.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 19, 2016 Dec. 31, 2025 In Use
70860-0777-21 70860-0777 Ondansetron hydrochloride Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous Feb. 15, 2021 Nov. 30, 2025 In Use
70860-0776-02 70860-0776 Ondansetron hydrochloride Ondansetron 2.0 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intramuscular, Intravenous June 30, 2018 Oct. 31, 2025 In Use
60687-0375-01 60687-0375 DRONABINOL DRONABINOL 2.5 mg/1 Ancillary Therapy Antiemetic Cannabinoid Oral July 16, 2018 Sept. 30, 2025 In Use
70934-0148-04 70934-0148 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 6, 2018 Aug. 31, 2025 In Use
00430-0720-24 00430-0720 Estradiol ESTRACE 0.5 mg/1 Hormonal Therapy Estrogen Oral Dec. 26, 2011 Aug. 31, 2025 In Use
00430-0721-24 00430-0721 Estradiol ESTRACE 1.0 mg/1 Hormonal Therapy Estrogen Oral Dec. 26, 2011 Aug. 31, 2025 In Use
00430-0722-24 00430-0722 Estradiol ESTRACE 2.0 mg/1 Hormonal Therapy Estrogen Oral Dec. 26, 2011 Aug. 31, 2025 In Use
00310-0512-95 00310-0512 Acalabrutinib Calquence 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BTK Oral April 1, 2020 July 31, 2025 In Use
51991-0891-33 51991-0891 Erlotinib Hydrochloride Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 July 31, 2025 In Use
51991-0892-33 51991-0892 Erlotinib Hydrochloride Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 July 31, 2025 In Use
69660-0202-91 69660-0202 Rucaparib Rubraca 250.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral May 1, 2017 July 31, 2025 In Use
69660-0203-91 69660-0203 Rucaparib Rubraca 300.0 mg/1 Chemotherapy Enzyme Inhibitor PARP Oral Dec. 19, 2016 July 31, 2025 In Use
00004-0350-09 00004-0350 Peginterferon alfa-2a Pegasys 180.0 ug/mL Immunotherapy Cytokine Interferon Subcutaneous Oct. 16, 2002 June 30, 2025 In Use
00378-3547-25 00378-3547 Mercaptopurine Mercaptopurine 50.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral July 1, 2005 June 30, 2025 In Use
70934-0634-95 70934-0634 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Aug. 31, 2020 May 31, 2025 In Use
00054-4550-15 00054-4550 Methotrexate sodium Methotrexate Sodium 2.5 mg/1 Chemotherapy Antimetabolite Folic Acid Analog Oral Aug. 1, 1994 May 31, 2025 In Use
71288-0112-90 71288-0112 Melphalan hydrochloride Melphalan hydrochloride Chemotherapy Alkylating Agent Nitrogen Mustard Intravenous June 30, 2019 April 30, 2025 In Use
68001-0534-36 68001-0534 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 31, 2022 April 29, 2025 In Use
76388-0880-25 76388-0880 Thioguanine Tabloid 40.0 mg/1 Chemotherapy Antimetabolite Purine Analog Oral March 12, 2013 March 31, 2025 In Use
00003-0830-50 00003-0830 Hydroxyurea Hydrea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral June 1, 2009 March 31, 2025 In Use
00781-3253-94 00781-3253 Azacitidine Azacitidine 100.0 mg/1 Chemotherapy Antimetabolite Pyrimidine Analog Intravenous, Subcutaneous Sept. 16, 2013 Feb. 28, 2025 In Use
70934-0809-83 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 22, 2021 Feb. 28, 2025 In Use
70934-0809-87 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 22, 2021 Feb. 28, 2025 In Use
70934-0809-95 70934-0809 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Dec. 8, 2020 Feb. 28, 2025 In Use
57962-0560-28 57962-0560 Ibrutinib IMBRUVICA 560.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor Bruton's Tyrosine Kinase (Btk) /BCR Oral Feb. 16, 2018 Feb. 28, 2025 In Use
70934-0318-10 70934-0318 Ondansetron Hydrochloride Ondansetron Hydrochloride 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral April 4, 2019 Feb. 28, 2025 In Use
70860-0785-05 70860-0785 Palonosetron hydrochloride Palonosetron Hydrochloride 0.05 mg/mL Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Intravenous Oct. 1, 2022 Feb. 28, 2025 In Use
70934-0634-84 70934-0634 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral July 13, 2021 Jan. 31, 2025 In Use
00955-1727-20 00955-1727 Oxaliplatin Oxaliplatin 5.0 mg/mL Chemotherapy Alkylating Agent Platinum Compound Intravenous July 7, 2014 Jan. 31, 2025 In Use
60505-6166-00 60505-6166 clofarabine Clofarabine 1.0 mg/mL Chemotherapy Antimetabolite Purine Analog Intravenous Jan. 1, 2018 Jan. 31, 2025 In Use
70934-0264-10 70934-0264 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral March 9, 2020 Jan. 31, 2025 In Use
70934-0264-12 70934-0264 Ondansetron Hydrochloride Ondansetron Hydrochloride 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Feb. 7, 2019 Jan. 31, 2025 In Use
49884-0290-01 49884-0290 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Aug. 8, 1988 Dec. 31, 2024 In Use
49884-0290-05 49884-0290 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Aug. 8, 1988 Dec. 31, 2024 In Use
60429-0265-01 60429-0265 Hydroxyurea Hydroxyurea 500.0 mg/1 Chemotherapy Miscellaneous Agent Antimetabolite/Organooxygen Oral Oct. 26, 2012 Dec. 31, 2024 In Use
60429-0433-01 60429-0433 Megestrol Acetate Megestrol Acetate 40.0 mg/1 Hormonal Therapy Progestin Analog Oral Sept. 4, 2015 Dec. 31, 2024 In Use
70860-0200-05 70860-0200 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 24, 2017 Dec. 31, 2024 In Use
70860-0200-50 70860-0200 Paclitaxel Paclitaxel 6.0 mg/mL Chemotherapy Antimitotic Agent Taxane Intravenous March 24, 2017 Dec. 31, 2024 In Use
70860-0219-20 70860-0219 decitabine Decitabine 50.0 mg/20mL Chemotherapy Antimetabolite Pyrimidine Analog Intravenous Aug. 15, 2021 Dec. 31, 2024 In Use

Found 10,000 results in 5 milliseconds — Export these results